Business Wire

Radisys Introduces Programmable Media Analytics to Monetize 5G & Edge Cloud Applications

23.2.2023 16:00:00 EET | Business Wire | Press release

Share

Radisys® Corporation, a global leader of open telecom solutions, today announced the addition of Engage Media Analytics within the acclaimed Engage Digital Platform (EDP). Engage Media Analytics is a comprehensive solution that provides Communication Service Providers (CSPs), System Integrators, and Enterprises with cost-effective low-code/no-code visual design tools to create Industry 4.0 applications with new AI-powered audio analytics and computer vision capabilities.

Engage Media Analytics’ application possibilities include notifying medical personnel when a patient in a wheelchair needs assistance or an elderly at-home patient has fallen from the bed; or identifying critical keywords or background sounds on an emergency call to augment the live agent discussion and help make life-saving decisions; detecting a fire in a factory, campus building, or other location and alerting emergency services personnel; monitoring retail shelves and combing customer identification, location, and live video to send money saving coupons to a frequent shopper’s phone as they near a location with promotional items; and many other Industry 4.0 services.

The Engage Media Analytics solution offers a unique combination of capabilities:

  • Off-the-shelf models including people and object counting, object and sound detection and classification, and biometric authentication. Engage Media Analytics also supports model customization and new model creation.
  • Ability to create trigger actions based on insights derived from the media stream whether through other communication capabilities in the EDP, including voice and video calling, creating an on-the-fly conference, sending alerts, and recording, as well as interworking with external systems for initiating business processes in enterprise workflow tools.
  • Distributed deployment of services spanning public and private clouds, network edge infrastructure, and on enterprise premises, enabling applications that demand low latency, cost and bandwidth-efficient network utilization for local breakout, and ensuring data privacy and security.

Alan Quayle, Founder TADHack, TADSummit, said: “The programmable communications industry (CPaaS) is evolving from a focus on connectivity to understanding the content of communications through programmable media analytics. Actionable intelligence and compliance are important in delivering innovative new services. The all-in-one Engage Digital Platform delivers AI-based actionable intelligence that enables service providers to deliver business efficiencies for their customers' mission-critical applications.”

Radisys’ Engage Media Analytics can be deployed on distributed edge cloud and integrates with public or private 4G/5G RAN and core network functions such as Network Exposure Function (NEF), abstracting complexities for application developers to productize Industry 4.0 applications quickly and cost-effectively.

Al Balasco, Head of Media and Application Solutions, Radisys, said: “The convergence and simultaneous maturity of multiple technologies like AI-based computer vision, 5G, edge cloud, and programmable communications opens new opportunities for service providers and system integrators to collaborate with enterprises in their digital transformation. Engage Media Analytics lets service providers combine the advantages of the bandwidth, low latency, Internet of Things (IoT) connectivity, and edge cloud resources to monetize public and private 5G networks and deliver customized solutions like predictive surveillance in smart cities, remote monitoring of enterprise campuses, business workflow automation for product quality assurance, traffic monitoring, and more.”

About Radisys

Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.radisys.com.

Radisys’ Engage Digital Platform is an award-winning programmable communications platform. Radisys' capacity-based versus consumption-based licensing approach for all products in the Engage Digital Platform offers a truly disruptive economic model relative to alternative programmable communications solutions. It dramatically improves the total cost of ownership (TCO) savings to 70% and greater over competitive cloud-based programmable communications and video analytics solutions, allowing service providers to reap the benefits.

For more information, visit www.engagedigital.ai.

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nereus for Radisys
Matt Baxter, +1-503-619-0505
radisys@nereus-worldwide.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye